Streamlined CRISPR guide RNA production for clinical and commercial success
Agilent ClinGuide CRISPR sgRNA brings more than 20 years of oligonucleotide development and manufacturing experience to clinical guide RNA production for human therapeutics. ClinGuide supports clinical CRISPR programs through controlled, high‑purity manufacturing processes, scalable production, and thorough analytical characterization.
This approach is informed by experience across seven commercial oligonucleotide therapeutics programs, helping establish the quality, consistency, and manufacturability required as CRISPR therapies progress.
Current good manufacturing practices—Ensure documentation, traceability, and quality with a partner committed to cGMP standards.
Manufacturing flexibility—Move seamlessly to manufacturing with two cGMP facilities in Colorado equipped for multiple projects.
Scientific expertise—Leverage 20+ years of oligo clinical and commercial program experience to accelerate success.
High purity—Ensure CRISPR purity with innovative methods confirmed by highly resolving analytics.
Rigorous quality systems—Meet regulatory standards through phase-appropriate quality systems and Quality-by-Design.
Strategic partnership—Collaborate with committed experts focused on your long-term therapeutic goals.
Clinical-Grade CRISPR sgRNA
Progress confidently from development to clinic with high-quality guide RNA
Browse brochures, flyers, and technical overviews to support your clinic‑to‑market journey
Advance oligo therapeutics from clinic to market
Produce high-quality oligo APIs in alignment with cGMP standards, with regulatory support, global market expertise, and scalable solutions—from grams to kilograms.
in U.S. and Canada are equipped for multiple modalities and projects
$1.65 billion
invested into CDMO business in 2023–2026
100+ successful audits
by pharma, biotech, and global regulatory agencies
id
benefits
id
videos
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Explore more ways to connect with us
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
